The Future of Ketamine and Mood Disorders In 2019, the FDA and European Commission authorized using an esketamine nasal spready underneath the model title Spravato to treat depression. Having said that, as of 2021, ketamine hasn't been accredited through the FDA to treat depression or other mental wellbeing disorders, and https://napoleonq529zce8.dreamyblogs.com/profile